DE19834007C1
(de)
*
|
1998-07-29 |
2000-02-24 |
Lohmann Therapie Syst Lts |
Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung
|
KR20010036685A
(ko)
*
|
1999-10-11 |
2001-05-07 |
김윤 |
펜타닐을 함유하는 매트릭스형 경피투여제
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
CN101843601A
(zh)
|
2000-04-26 |
2010-09-29 |
沃特森药物公司 |
最小化与奥昔布宁疗法有关的副作用
|
US7029694B2
(en)
*
|
2000-04-26 |
2006-04-18 |
Watson Laboratories, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
US20030124177A1
(en)
*
|
2000-04-26 |
2003-07-03 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
US7179483B2
(en)
*
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
USRE44145E1
(en)
|
2000-07-07 |
2013-04-09 |
A.V. Topchiev Institute Of Petrochemical Synthesis |
Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
|
US20020119187A1
(en)
*
|
2000-09-29 |
2002-08-29 |
Cantor Adam S. |
Composition for the transdermal delivery of fentanyl
|
US20050208117A1
(en)
*
|
2001-03-16 |
2005-09-22 |
Venkatraman Subramanian S |
Transdermal administration of fentanyl and analogs thereof
|
DE60220661T2
(de)
*
|
2001-03-16 |
2008-02-14 |
Alza Corp., Mountain View |
Transdermales pflaster zur verabreichung von fentanyl
|
DE20220982U1
(de)
|
2001-03-16 |
2004-11-25 |
Alza Corp., Mountain View |
Transdermal-Pflaster zum Verabreichen von Fentanyl
|
US8206738B2
(en)
|
2001-05-01 |
2012-06-26 |
Corium International, Inc. |
Hydrogel compositions with an erodible backing member
|
US20050215727A1
(en)
|
2001-05-01 |
2005-09-29 |
Corium |
Water-absorbent adhesive compositions and associated methods of manufacture and use
|
US20050113510A1
(en)
|
2001-05-01 |
2005-05-26 |
Feldstein Mikhail M. |
Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
|
US8541021B2
(en)
|
2001-05-01 |
2013-09-24 |
A.V. Topchiev Institute Of Petrochemical Synthesis |
Hydrogel compositions demonstrating phase separation on contact with aqueous media
|
WO2002087642A2
(en)
|
2001-05-01 |
2002-11-07 |
A.V. Topchiev Institute Of Petrochemical Synthesis |
Two-phase, water-absorbent bioadhesive composition
|
US8840918B2
(en)
|
2001-05-01 |
2014-09-23 |
A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences |
Hydrogel compositions for tooth whitening
|
CA2445086C
(en)
|
2001-05-01 |
2008-04-08 |
A.V. Topchiev Institute Of Petrochemical Synthesis |
Hydrogel compositions
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
WO2003024450A1
(en)
*
|
2001-09-20 |
2003-03-27 |
Eisai Co., Ltd. |
Methods for treating prion diseases
|
EP1446110A2
(en)
*
|
2001-10-16 |
2004-08-18 |
Structural Bioinformatics Inc. |
Organosulfur inhibitors of tyrosine phosphatases
|
WO2003032914A2
(en)
*
|
2001-10-17 |
2003-04-24 |
Eisai Co., Ltd. |
Methods for treating substance abuse with cholinesterase inhibitors
|
WO2003063927A2
(en)
*
|
2001-11-16 |
2003-08-07 |
Eisai Co. Ltd |
Compositions and methods to treat gastrointestinal disorders
|
AU2002366796A1
(en)
*
|
2001-12-19 |
2003-07-09 |
Eisai Co. Ltd |
Methods using proton pump inhibitors
|
US7921999B1
(en)
*
|
2001-12-20 |
2011-04-12 |
Watson Laboratories, Inc. |
Peelable pouch for transdermal patch and method for packaging
|
JP2005526839A
(ja)
|
2002-04-23 |
2005-09-08 |
アルザ・コーポレーシヨン |
不正使用の可能性が低い経皮鎮痛薬システム
|
GB0210397D0
(en)
*
|
2002-05-07 |
2002-06-12 |
Ferring Bv |
Pharmaceutical formulations
|
AU2003229016A1
(en)
*
|
2002-05-10 |
2003-11-11 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
|
AU2003298514A1
(en)
*
|
2002-05-17 |
2004-05-04 |
Eisai Co., Ltd. |
Methods and compositions using cholinesterase inhibitors
|
WO2003097011A1
(en)
*
|
2002-05-17 |
2003-11-27 |
Eisai Co., Ltd. |
Compositions and methods using proton pump inhibitors
|
US20070053976A1
(en)
*
|
2002-05-17 |
2007-03-08 |
Eisai R & D Management Co., Ltd. |
Novel combination of drugs as antidepressant
|
US7217853B2
(en)
|
2002-05-24 |
2007-05-15 |
Corium International, Inc. |
Composition for cushions, wound dressings and other skin-contacting products
|
PL206314B1
(pl)
*
|
2002-05-31 |
2010-07-30 |
Sabalo Nvsabalo Nv |
Roztwór wodny zawierający kwas borowy i niekoloidowy kwas krzemowy oraz dodatek pochłaniający wodę, sposób jego wytwarzania i jego zastosowanie
|
AU2003248747A1
(en)
|
2002-06-27 |
2004-01-19 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
US20040009180A1
(en)
*
|
2002-07-11 |
2004-01-15 |
Allergan, Inc. |
Transdermal botulinum toxin compositions
|
US20040086551A1
(en)
*
|
2002-10-30 |
2004-05-06 |
Miller Kenneth J. |
Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
|
WO2004073696A1
(de)
*
|
2003-02-21 |
2004-09-02 |
Schering Ag |
Uv-stabiles transdermales pflaster
|
CA2516618A1
(en)
*
|
2003-02-27 |
2004-09-10 |
Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. |
Pharmaceutical composition for treatment of drug dependence
|
US7244739B2
(en)
*
|
2003-05-14 |
2007-07-17 |
Torreypines Therapeutics, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
US7057100B2
(en)
*
|
2003-06-26 |
2006-06-06 |
The J.C. Robinson Seed Co. |
Inbred corn line W23129
|
US8524272B2
(en)
*
|
2003-08-15 |
2013-09-03 |
Mylan Technologies, Inc. |
Transdermal patch incorporating active agent migration barrier layer
|
CA2536173A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
US20060286158A1
(en)
*
|
2003-10-17 |
2006-12-21 |
Calvert Murrell George A |
Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents
|
US20070053966A1
(en)
*
|
2003-10-17 |
2007-03-08 |
Robert Ang |
Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue
|
US20060286159A1
(en)
*
|
2003-10-17 |
2006-12-21 |
Calvert Murrell George A |
Treatment of persistent active tendinopathy using transdermal glyceryl trinitrate providing durability of effect
|
US20070059351A1
(en)
*
|
2003-10-17 |
2007-03-15 |
Murrell George A C |
Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods
|
JP2007527415A
(ja)
|
2003-10-30 |
2007-09-27 |
アルザ・コーポレーシヨン |
乱用の可能性が低い経皮鎮痛剤システム
|
US8668925B2
(en)
|
2003-12-12 |
2014-03-11 |
Bayer Intellectual Property Gmbh |
Transdermal delivery of hormones without the need of penetration enhancers
|
WO2005067910A1
(ja)
*
|
2004-01-20 |
2005-07-28 |
Saitama Daiichi Pharmaceutical Co., Ltd. |
ツロブテロール貼付剤
|
CA2554716A1
(en)
*
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
RU2380092C2
(ru)
|
2004-01-30 |
2010-01-27 |
Кориум Интернэшнл, Инк. |
Быстро растворяющаяся пленка для доставки активного агента
|
WO2005090370A1
(en)
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
EP1768968A1
(en)
|
2004-05-20 |
2007-04-04 |
Foldrx Pharmaceuticals, Inc. |
2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
|
EP1765332A2
(en)
*
|
2004-06-17 |
2007-03-28 |
Cengent Therapeutics, Inc. |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
EP1786421A2
(en)
*
|
2004-07-09 |
2007-05-23 |
Cengent Therapeutics, Inc. |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
EP1791575B1
(en)
|
2004-08-05 |
2014-10-08 |
Corium International, Inc. |
Adhesive composition
|
JP4824963B2
(ja)
*
|
2004-08-12 |
2011-11-30 |
日東電工株式会社 |
貼付材及び貼付製剤
|
JP4745747B2
(ja)
*
|
2004-08-12 |
2011-08-10 |
日東電工株式会社 |
フェンタニル含有貼付製剤
|
WO2006028970A1
(en)
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
EP2433634A3
(en)
|
2004-09-17 |
2012-07-18 |
The Whitehead Institute for Biomedical Research |
Compounds, compositions and methods of inhibiting a-synuclein toxicity
|
US8067464B2
(en)
|
2004-10-04 |
2011-11-29 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
US8252320B2
(en)
*
|
2004-10-21 |
2012-08-28 |
Durect Corporation |
Transdermal delivery system for sufentanil
|
EP1814531B1
(en)
*
|
2004-10-21 |
2010-06-16 |
Durect Corporation |
Transdermal delivery systems
|
AU2006206249A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nicox S.A. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
CA2597422A1
(en)
*
|
2005-02-16 |
2007-08-02 |
Nitromed, Inc. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
TW200640526A
(en)
*
|
2005-02-24 |
2006-12-01 |
Alza Corp |
Transdermal electrotransport drug delivery systems with reduced abuse potential
|
WO2006093864A1
(en)
*
|
2005-02-28 |
2006-09-08 |
Nitromed, Inc. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
EP1861093A2
(en)
*
|
2005-03-09 |
2007-12-05 |
Nitromed, Inc. |
Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
|
ATE534652T1
(de)
|
2005-04-01 |
2011-12-15 |
Univ California |
Phosphono-pent-2-en-1-yl-nukleoside und analoga
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
US20060270709A1
(en)
|
2005-04-04 |
2006-11-30 |
Eisai Co. Ltd. |
Dihydropyridine compounds and compositions for headaches
|
US8962013B2
(en)
*
|
2005-05-02 |
2015-02-24 |
Bayer Intellectual Property Gmbh |
Multi-layered transdermal system with triazine UV absorber
|
WO2006127591A2
(en)
*
|
2005-05-23 |
2006-11-30 |
Nitromed, Inc. |
Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
US20070014839A1
(en)
*
|
2005-07-18 |
2007-01-18 |
Stefan Bracht |
Decomposer film for transdermal patches
|
WO2007016677A2
(en)
|
2005-08-02 |
2007-02-08 |
Nitromed, Inc. |
Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
WO2007035940A2
(en)
*
|
2005-09-23 |
2007-03-29 |
Alza Corporation |
Transdermal norelgestromin delivery system
|
WO2007035941A2
(en)
*
|
2005-09-23 |
2007-03-29 |
Alza Corporation |
Transdermal galantamine delivery system
|
WO2007035939A2
(en)
|
2005-09-23 |
2007-03-29 |
Alza Corporation |
High enhancer-loading polyacrylate formulation for transdermal applications
|
EP1942909A4
(en)
*
|
2005-10-04 |
2010-01-06 |
Nitromed Inc |
METHODS OF TREATING RESPIRATORY DISORDERS
|
EP1945030A4
(en)
*
|
2005-10-04 |
2009-10-21 |
Nitromed Inc |
ASSESSING GENETIC RISK IN CARDIAC INSUFFICIENCIES: THE IMPACT OF THE GENETIC VARIATION OF GLY389ARG POLYMORPHISM OF THE BETA ADRENERGIC RECEPTOR 1
|
WO2007056105A2
(en)
|
2005-11-02 |
2007-05-18 |
Transpharma Medical Ltd. |
Human growth hormone patch formulations
|
US7888422B2
(en)
|
2005-11-09 |
2011-02-15 |
Mylan Technologies Inc. |
Long-wearing removable pressure sensitive adhesive
|
US7838023B2
(en)
*
|
2005-11-16 |
2010-11-23 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
US8318181B2
(en)
|
2005-12-01 |
2012-11-27 |
University Of Massachusetts Lowell |
Botulinum nanoemulsions
|
US9486408B2
(en)
|
2005-12-01 |
2016-11-08 |
University Of Massachusetts Lowell |
Botulinum nanoemulsions
|
EP1968584A2
(en)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
EP1971340A2
(en)
*
|
2005-12-22 |
2008-09-24 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
US20070202155A1
(en)
*
|
2006-02-03 |
2007-08-30 |
Cure Therapeutics, Inc. |
Low dose no donor-containing transdermal patch
|
BRPI0709699A2
(pt)
*
|
2006-03-29 |
2011-07-26 |
Foldrx Pharmaceuticals Inc |
inibiÇço da toxidez da alfa-sinucleina
|
US20090306027A1
(en)
*
|
2006-04-10 |
2009-12-10 |
Nitomed, Inc. |
Genetic risk assessment in heart failure: impact of the genetic variation of g-protein beta 3 subunit polymorphism
|
US20070259026A1
(en)
*
|
2006-04-20 |
2007-11-08 |
Robert Ang |
Vasodialating dressing for use with intravenous catheters
|
DE102006019293A1
(de)
*
|
2006-04-21 |
2007-10-25 |
LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH |
Pflaster, enthaltend ein Fentanyl Analogum
|
WO2008039245A2
(en)
|
2006-04-27 |
2008-04-03 |
Anterios, Inc. |
Assessment of the effects of topical administration of chemodenervating pharmaceuticals
|
US20090123527A1
(en)
*
|
2006-07-24 |
2009-05-14 |
Akorn, Inc. |
Method of inducing topical anesthesia and transdermal patch
|
US8541467B2
(en)
|
2006-08-16 |
2013-09-24 |
Action Medicines, S.L. |
Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
|
EA021255B1
(ru)
|
2006-08-28 |
2015-05-29 |
Киова Хакко Кирин Ко., Лимитед |
Антагонистические моноклональные антитела человека, специфичные в отношении light человека
|
DK2117521T3
(da)
|
2006-11-03 |
2012-09-03 |
Durect Corp |
Transdermale indgivelsessystemer omfattende bupivacain
|
KR101518077B1
(ko)
|
2006-12-01 |
2015-05-28 |
안테리오스, 인코퍼레이티드 |
펩티드 나노입자 및 이의 용도
|
CN101848702B
(zh)
|
2006-12-01 |
2013-07-17 |
安特里奥公司 |
两亲实体纳米粒子
|
US20080131491A1
(en)
*
|
2006-12-01 |
2008-06-05 |
Akinori Hanatani |
Percutaneously absorbable preparation
|
WO2008066185A1
(fr)
*
|
2006-12-01 |
2008-06-05 |
Nitto Denko Corporation |
Procédé destiné à prévenir la décoloration provoquée par le temps d'une préparation d'adhésif cutané contenant du donépézil
|
JP5227041B2
(ja)
*
|
2007-02-28 |
2013-07-03 |
日東電工株式会社 |
薬物含有貼付製剤
|
JP2010520154A
(ja)
*
|
2007-03-05 |
2010-06-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
神経変性疾患のためのampaレセプターアンタゴニストおよびnmdaレセプターアンタゴニスト
|
US20080226702A1
(en)
*
|
2007-03-16 |
2008-09-18 |
Endo Pharmaceuticals, Inc. |
Transdermal Delivery Form Disposal Systems and Methods
|
WO2008139984A1
(en)
*
|
2007-04-26 |
2008-11-20 |
Eisai R & D Management Co., Ltd. |
Cinnamide compounds for dementia
|
WO2008144320A2
(en)
*
|
2007-05-17 |
2008-11-27 |
Endo Pharmaceuticals, Inc. |
Opioid and methods of making and using the same
|
ES2660906T3
(es)
|
2007-05-31 |
2018-03-26 |
Anterios, Inc. |
Nanopartículas de ácido nucleico y usos de las mismas
|
AU2008283929B2
(en)
|
2007-08-06 |
2013-10-10 |
Serenity Pharmaceuticals, Llc |
Methods and devices for desmopressin drug delivery
|
WO2009026178A2
(en)
*
|
2007-08-17 |
2009-02-26 |
Arcion Therapeutics, Inc. |
High concentration local anesthetic formulations
|
US9017301B2
(en)
*
|
2007-09-04 |
2015-04-28 |
Mylan Technologies, Inc. |
Transdermal drug delivery systems comprising a coated release liner
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
CN101902996B
(zh)
|
2007-10-15 |
2014-11-26 |
阿尔扎公司 |
芬太尼的一天更换一次透皮施用
|
JP5209433B2
(ja)
*
|
2007-10-19 |
2013-06-12 |
日東電工株式会社 |
貼付製剤
|
US8426587B2
(en)
|
2007-11-21 |
2013-04-23 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
EP2111857A1
(de)
*
|
2008-04-25 |
2009-10-28 |
Acino AG |
Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
|
EP2712622B1
(en)
|
2008-05-21 |
2016-07-13 |
Ferring B.V. |
Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
|
US20100286045A1
(en)
|
2008-05-21 |
2010-11-11 |
Bjarke Mirner Klein |
Methods comprising desmopressin
|
US11963995B2
(en)
|
2008-05-21 |
2024-04-23 |
Ferring B.V. |
Methods comprising desmopressin
|
US20110056863A1
(en)
*
|
2008-05-30 |
2011-03-10 |
Junichi Sekiya |
Adhesive preparation containing donepezil, and package of the same
|
WO2009145269A1
(ja)
*
|
2008-05-30 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
経皮吸収製剤
|
US20110212157A1
(en)
|
2008-06-26 |
2011-09-01 |
Anterios, Inc. |
Dermal delivery
|
EP2318035B1
(en)
|
2008-07-01 |
2019-06-12 |
Curemark, Llc |
Methods and compositions for the treatment of symptoms of neurological and mental health disorders
|
US8235929B2
(en)
*
|
2008-07-15 |
2012-08-07 |
Griffin Santea B |
Method of treating pruritis
|
WO2010019953A1
(en)
|
2008-08-15 |
2010-02-18 |
Arcion Therapeutics, Inc. |
High concentration local anesthetic formulations for treating non-neuropathic pain
|
ES2882518T3
(es)
|
2009-01-06 |
2021-12-02 |
Galenagen Llc |
Composición que comprende proteasa, amilasa y lipasa
|
KR20170005191A
(ko)
|
2009-01-06 |
2017-01-11 |
큐어론 엘엘씨 |
이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
|
US8784879B2
(en)
|
2009-01-14 |
2014-07-22 |
Corium International, Inc. |
Transdermal administration of tamsulosin
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
US8920392B2
(en)
|
2009-05-05 |
2014-12-30 |
Watson Laboratories, Inc. |
Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
EP2295046B1
(de)
|
2009-09-14 |
2012-12-19 |
Acino AG |
Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
CA2796575C
(en)
|
2010-04-13 |
2018-05-15 |
Relmada Therapeutics, Inc. |
Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
|
US9173855B2
(en)
|
2010-11-02 |
2015-11-03 |
Sekisui Medical Co., Ltd. |
Patch
|
WO2012095548A2
(es)
|
2011-01-13 |
2012-07-19 |
Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) |
Compuestos para el tratamiento de enfermedades neurodegenerativas
|
AU2012209274A1
(en)
|
2011-01-24 |
2013-09-12 |
Anterios, Inc. |
Nanoparticle compositions, formulations thereof, and uses therefor
|
DK2667854T3
(en)
|
2011-01-24 |
2019-04-23 |
Anterios Inc |
NANO PARTICLE FORMATIONS
|
WO2012103037A1
(en)
|
2011-01-24 |
2012-08-02 |
Anterios, Inc. |
Oil compositions
|
PT2683385T
(pt)
|
2011-03-10 |
2018-10-19 |
Rigel Pharmaceuticals Inc |
Pirimidinadiaminas 2,4-substituídas para utilização no lúpus discoide
|
ES2804223T3
(es)
|
2011-04-21 |
2021-02-04 |
Curemark Llc |
Compuestos para el tratamiento de Trastornos Neuropsiquiátricos
|
KR20140042868A
(ko)
|
2011-06-23 |
2014-04-07 |
맵 파마슈티컬스, 인코포레이티드 |
신규한 플루오로에르골린 유사체
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
EP2599478A1
(de)
|
2011-11-30 |
2013-06-05 |
Acino AG |
Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff davon
|
SG10201509139QA
(en)
|
2011-12-19 |
2015-12-30 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
SG11201403433PA
(en)
|
2011-12-21 |
2014-07-30 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
WO2013163176A1
(en)
|
2012-04-23 |
2013-10-31 |
Allertein Therapeutics, Llc |
Nanoparticles for treatment of allergy
|
ES2668300T3
(es)
|
2012-05-02 |
2018-05-17 |
Boehringer Ingelheim International Gmbh |
Inhibidores de SSAO de 3-haloamidina sustituida y usos de los mismos
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
WO2013187965A1
(en)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
WO2014012653A1
(en)
*
|
2012-07-16 |
2014-01-23 |
Grünenthal GmbH |
Pharmaceutical patch for transdermal administration of tapentadol
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
WO2014043257A1
(en)
|
2012-09-12 |
2014-03-20 |
Rigel Pharmaceuticals, Inc. |
Treatment for vitiligo
|
US9169214B2
(en)
|
2012-12-21 |
2015-10-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
|
BR112015014964A2
(pt)
|
2012-12-21 |
2017-07-11 |
Map Pharmaceuticals Inc |
novos derivados de metisergida
|
US9072682B2
(en)
|
2012-12-31 |
2015-07-07 |
Mylan Inc. |
Transdermal dosage form for low-melting point active agent
|
AU2014248090B2
(en)
|
2013-04-03 |
2018-08-02 |
N-Fold Llc |
Novel nanoparticle compositions
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
EP2821071A1
(en)
|
2013-07-04 |
2015-01-07 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Compounds for breast cancer treatment
|
WO2015007326A1
(en)
|
2013-07-18 |
2015-01-22 |
Institut D'investigació Biomèdica De Bellvitge (Idibell) |
Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
EP2930238A1
(en)
|
2014-04-09 |
2015-10-14 |
Fundacio Centre de Regulacio Genomica |
Compositions for treating cancer
|
US9044390B1
(en)
|
2014-04-17 |
2015-06-02 |
Gary J. Speier |
Pharmaceutical composition and method of manufacturing
|
US9186386B2
(en)
|
2014-04-17 |
2015-11-17 |
Gary J. Speier |
Pharmaceutical composition and method of manufacturing
|
US9649266B2
(en)
|
2014-05-01 |
2017-05-16 |
Anterios, Inc. |
Methods to treat, prevent, and improve skin conditions
|
EP2949324A1
(en)
|
2014-05-27 |
2015-12-02 |
Consorci Institut Catala de Ciencies Cardiovasculars |
Prevention and/or treatment of ischemia/reperfusion injury
|
KR102433464B1
(ko)
|
2014-05-28 |
2022-08-17 |
아게누스 인코포레이티드 |
항-gitr 항체 및 이의 사용 방법
|
PT3372229T
(pt)
|
2014-06-06 |
2021-06-17 |
Ovid Therapeutics Inc |
Métodos para aumentar a inibição tónica e tratar a síndrome de angelman
|
EP2957634A1
(en)
|
2014-06-20 |
2015-12-23 |
Consejo Superior De Investigaciones Científicas |
Compounds for prevention and/or treatment of fibrotic diseases
|
EP2977463A1
(en)
|
2014-07-25 |
2016-01-27 |
Centro de Investigación Biomédica en Red (CIBER) |
Methods and agents related to lung diseases
|
EP3179857B1
(en)
|
2014-08-14 |
2021-09-08 |
Mamoun M. Alhamadsheh |
Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
|
EP2987503A1
(en)
|
2014-08-22 |
2016-02-24 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Methods and reagents for prevention and/or treatment of infection
|
EP2997977A1
(en)
|
2014-09-19 |
2016-03-23 |
Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe |
Specific mtor inhibitors in the treatment of x-linked adrenoleukodystrophy
|
CN114230664A
(zh)
|
2014-12-11 |
2022-03-25 |
皮埃尔法布雷医药公司 |
抗c10orf54抗体及其用途
|
EP3789039A1
(en)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
MX2017009406A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo isoergolina y usos de estos.
|
AU2016209492B2
(en)
|
2015-01-20 |
2020-10-22 |
Xoc Pharmaceuticals, Inc |
Ergoline compounds and uses thereof
|
DE112016001013T5
(de)
|
2015-03-03 |
2017-12-21 |
Kymab Limited |
Antikörper, verwendungen und verfahren
|
EP3067369A1
(en)
|
2015-03-11 |
2016-09-14 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Methods and compositions for the treatment of anti-angiogenic resistant cancer
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
EP3289104B1
(en)
|
2015-04-29 |
2020-11-04 |
New York University |
Method for treating high-grade gliomas
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
US9962340B2
(en)
|
2015-06-09 |
2018-05-08 |
Life Tech Global, Llc |
Device and method for the transdermal delivery of cannabidiol
|
US9682069B2
(en)
|
2015-07-17 |
2017-06-20 |
Ovid Therapeutics Inc |
Methods of treating Dravet syndrome
|
PE20190338A1
(es)
|
2015-07-17 |
2019-03-07 |
Ovid Therapeutics Inc |
Metodos de tratamiento de trastornos del desarrollo con gaboxadol
|
ES2781332T3
(es)
|
2015-07-24 |
2020-09-01 |
Glaxo Group Ltd |
Tratamiento para el vitíligo
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
US10272125B2
(en)
*
|
2015-09-14 |
2019-04-30 |
Life Tech Global, Llc |
Transdermal delivery of cannabidiol with other active moieties including cannabinoids
|
EP3356384B1
(en)
|
2015-09-29 |
2023-11-29 |
Paris Sciences et Lettres |
Polypeptides comprising vinculin binding sites for the treatment of proliferation and/or adhesion related diseases
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
US10493049B2
(en)
|
2016-02-10 |
2019-12-03 |
Niracle LLC |
Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
|
WO2017151836A1
(en)
|
2016-03-04 |
2017-09-08 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
WO2017156183A1
(en)
|
2016-03-08 |
2017-09-14 |
Los Gatos Pharmaceuticals, Inc. |
Camptothecin derivatives and uses thereof
|
EP3426301A4
(en)
|
2016-03-08 |
2019-11-06 |
Los Gatos Pharmaceuticals, Inc. |
VERBUNDNANOPARTICLES AND USES THEREOF
|
EP3219326A1
(en)
|
2016-03-14 |
2017-09-20 |
Institut Catalá De Ciencies Cardiovasculars (ICCC) |
Prevention and/or treatment of ischemia or ischemia/reperfusion injury
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
DK3454904T3
(da)
|
2016-05-13 |
2023-02-06 |
Pasteur Institut |
Inhibering af beta-2-nikotiniske acetylcholinreceptorer til at behandle patologi ved Alzheimers sygdom
|
US10653639B2
(en)
|
2016-05-16 |
2020-05-19 |
Cv Sciences, Inc. |
Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction
|
SG10201912563XA
(en)
|
2016-05-27 |
2020-02-27 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
JP2019525772A
(ja)
|
2016-07-08 |
2019-09-12 |
スターテン・バイオテクノロジー・ベー・フェー |
抗apoc3抗体およびその使用方法
|
FI127620B
(fi)
*
|
2016-07-12 |
2018-10-31 |
Tarmo Pekkarinen |
Nuuskantyyppinen nikotiini-pellavansiemenrouhekoostumus
|
WO2018035281A1
(en)
|
2016-08-17 |
2018-02-22 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
US10660967B2
(en)
|
2016-10-21 |
2020-05-26 |
Augusta University Research Institute, Inc. |
Curcumin conjugates and methods of use thereof
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
KR102431830B1
(ko)
|
2016-11-07 |
2022-08-16 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
JP2019535829A
(ja)
|
2016-11-21 |
2019-12-12 |
エイリオン セラピューティクス, インコーポレイテッド |
大型薬剤の経皮送達
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
AU2017373945A1
(en)
|
2016-12-07 |
2019-06-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
MX2019006340A
(es)
|
2016-12-07 |
2019-11-07 |
Agenus Inc |
Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
|
US10071083B2
(en)
|
2017-02-03 |
2018-09-11 |
Ovid Therapeutics Inc |
Use of gaboxadol in the treatment of tinnitus
|
WO2018151867A1
(en)
|
2017-02-17 |
2018-08-23 |
CAMRIS International, Inc. |
Universal antivenom
|
BR112019016935A2
(pt)
|
2017-02-17 |
2020-04-07 |
Eidos Therapeutics Inc |
processos para preparação de ag-10, seus intermediários e sais dos mesmos
|
WO2018162581A1
(en)
|
2017-03-07 |
2018-09-13 |
OP2 Drugs |
Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
|
EP3385276A1
(en)
|
2017-04-03 |
2018-10-10 |
Targedys |
Proteins derived from clpb and uses thereof
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
WO2018193427A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
MA50957A
(fr)
|
2017-05-01 |
2020-10-14 |
Agenus Inc |
Anticorps anti-tigit et leurs méthodes d'utilisation
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
AU2018275873A1
(en)
|
2017-06-01 |
2019-12-19 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
US10323289B2
(en)
|
2017-06-26 |
2019-06-18 |
Institut Pasteur |
Treatments to eliminate HIV reservoirs and reduce viral load
|
CN111315774B
(zh)
|
2017-06-27 |
2023-12-22 |
纽洛可科学有限公司 |
抗fam19a5抗体及其用途
|
US11746149B2
(en)
|
2017-06-27 |
2023-09-05 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
|
KR20220031738A
(ko)
|
2017-06-27 |
2022-03-11 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
EP3645039A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
|
WO2019046556A1
(en)
|
2017-09-01 |
2019-03-07 |
East Carolina University |
COMPOUNDS, COMPOSITIONS, KITS AND METHODS FOR ACTIVATING IMMUNE CELLS AND / OR AN IMMUNE SYSTEM RESPONSE
|
EP3569228A1
(en)
|
2018-05-17 |
2019-11-20 |
Association pour la recherche à l'IGBMC (ARI) |
Non-steroidal selective glucocorticoid receptor agonistic modulators (segrams) and uses thereof
|
FI3700513T3
(fi)
|
2017-10-27 |
2022-12-15 |
|
Ei-steroidiset selektiiviset glukortikoidireseptorin agonistimodulaattorit (segramit) ja niiden käyttö
|
MA50516A
(fr)
|
2017-10-31 |
2020-09-09 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs procédés d'utilisation
|
US10953036B2
(en)
|
2017-11-20 |
2021-03-23 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods of modulating HIF-2A to improve muscle generation and repair
|
EP3728295A1
(en)
|
2017-12-20 |
2020-10-28 |
Allergan, Inc. |
Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders
|
WO2019152808A1
(en)
|
2018-02-01 |
2019-08-08 |
Yale University |
Compositions and methods for inhibition of nuclear-penetrating antibodies
|
EP3539975A1
(en)
|
2018-03-15 |
2019-09-18 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Micropeptides and uses thereof
|
AU2019239291A1
(en)
|
2018-03-23 |
2020-10-08 |
Eidos Therapeutics, Inc. |
Methods of treating TTR amyloidosis using AG10
|
KR20240060864A
(ko)
|
2018-04-24 |
2024-05-08 |
주식회사 뉴라클사이언스 |
신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
|
CN112119091A
(zh)
|
2018-05-10 |
2020-12-22 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
AU2019321583A1
(en)
|
2018-08-17 |
2021-01-21 |
Eidos Therapeutics, Inc. |
Formulations of AG10
|
AU2019336943A1
(en)
|
2018-09-06 |
2021-03-18 |
OP2 Drugs |
Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof
|
JP2022500452A
(ja)
|
2018-09-13 |
2022-01-04 |
エイリオン セラピューティクス, インコーポレイテッド |
プラスミノーゲンアクチベーターインヒビター1(plasminogen activator inhibitor 1)(PAI−1)阻害剤(inhibitor)の使用
|
CN113056268A
(zh)
|
2018-09-13 |
2021-06-29 |
艾里奥治疗公司 |
纤溶酶原激活物抑制剂1(pai-1)抑制剂和其用途
|
JP2022504287A
(ja)
|
2018-10-03 |
2022-01-13 |
スターテン・バイオテクノロジー・ベー・フェー |
ヒト及びカニクイザルapoc3に特異的な抗体、並びにその使用の方法
|
CA3119341A1
(en)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
WO2020117564A1
(en)
|
2018-12-03 |
2020-06-11 |
Eirion Therapeutics, Inc. |
Improved delivery of large agents
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
US11447468B2
(en)
|
2019-02-06 |
2022-09-20 |
Dice Alpha, Inc. |
IL-17 ligands and uses thereof
|
EP4378958A2
(en)
|
2019-02-26 |
2024-06-05 |
Inspirna, Inc. |
High-affinity anti-mertk antibodies and uses thereof
|
SG11202110518XA
(en)
|
2019-05-14 |
2021-10-28 |
Eirion Therapeutics Inc |
Delaying peak effect and/or extending duration of response
|
JP2022532924A
(ja)
|
2019-05-20 |
2022-07-20 |
ニルバナ サイエンシーズ インク. |
発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
MX2022003166A
(es)
|
2019-09-16 |
2022-06-29 |
Dice Alpha Inc |
Moduladores de il-17a y usos de los mismos.
|
US20240166770A1
(en)
|
2019-10-18 |
2024-05-23 |
Yale University |
Compositions and methods for inhibition of cell-penetrating antibodies
|
AU2021207586A1
(en)
|
2020-01-13 |
2022-07-21 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody
|
JP2023512657A
(ja)
|
2020-02-05 |
2023-03-28 |
ワシントン・ユニバーシティ |
Il-7タンパク質とcar保有免疫細胞の組み合わせで固形腫瘍を治療する方法
|
US11850220B2
(en)
|
2020-05-19 |
2023-12-26 |
Augusta University Research Institute, Inc. |
Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
WO2022093718A1
(en)
|
2020-10-26 |
2022-05-05 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
WO2022094475A1
(en)
|
2020-11-02 |
2022-05-05 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
KR20230104175A
(ko)
|
2020-11-05 |
2023-07-07 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질과 뉴클레오타이드 백신의 조합물을 사용한 종양의 치료 방법
|
US11858908B2
(en)
|
2021-01-19 |
2024-01-02 |
Augusta University Research Institute, Inc. |
Compositions and methods for inhibiting IDO1
|
US20240208968A1
(en)
|
2021-03-10 |
2024-06-27 |
Dice Molecules Sv, Inc. |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
JP2024522213A
(ja)
|
2021-06-14 |
2024-06-11 |
アルジェニクス ビーブイ |
抗il-9抗体及びその使用方法
|
CA3236150A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
WO2023081539A1
(en)
|
2021-11-08 |
2023-05-11 |
Weiyong Li |
Transdermal drug delivery system for delivering a drug to a patient
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
WO2023130081A1
(en)
|
2021-12-30 |
2023-07-06 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and vegf antagonist
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
WO2024086852A1
(en)
|
2022-10-21 |
2024-04-25 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|